{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:11:12Z","timestamp":1779127872923,"version":"3.51.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of adjunctive therapies for proliferative vitreoretinopathy (PVR) related to rhegmatogenous retinal detachment (RRD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic literature search was conducted on Ovid MEDLINE, Embase, and the Cochrane Library for randomized controlled trials (RCTs) from January 2000 to December 2025. A Bayesian random-effects network meta-analysis was used to compare different therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 2,519 patients from 18 RCTs were included (1,339 receiving adjunctive treatments and 1,180 receiving placebo). Oral retinoic acid was associated with significantly higher primary (hazard ratio [HR] = 2.86, 95% CI = [1.16, 7.53]) and final (HR = 2.90, 95% CI = [1.12, 7.50]) retinal reattachment rates, improved visual acuity (MD=\u22120.89, 95% CI = [\u22121.68, \u22120.08]), and a lower incidence of postoperative macular pucker (HR = 0.12, 95% CI = [0.02, 0.50]) compared with placebo. Oral prednisolone had a lower rate of PVR recurrence compared with placebo (HR = 0.37, 95% CI = [0.17, 0.79]), while oral retinoic acid (HR = 0.06, 95% CI = [0.00, 0.50]) and intravitreal dexamethasone (HR = 0.23, 95% CI = [0.05, 0.81]) were associated with reduced rates of RRD reoperation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Oral retinoic acid ranked highest for primary outcomes in PVR associated with RRD; however, this finding was driven by a single RCT with limited sample size. Oral prednisolone reduced PVR recurrence, while intravitreal dexamethasone lowered reoperation risk, compared with placebo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004789","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T21:00:50Z","timestamp":1770930050000},"page":"977-985","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["THERAPEUTICS FOR MANAGEMENT OF PROLIFERATIVE VITREORETINOPATHY RELATED TO RHEGMATOGENOUS RETINAL DETACHMENT"],"prefix":"10.1097","volume":"46","author":[{"given":"Ryan S.","family":"Huang","sequence":"first","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay E.","family":"Kuriyan","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2173-0021","authenticated-orcid":false,"given":"Rafael N.","family":"Miranda","sequence":"additional","affiliation":[{"name":"Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0927-3086","authenticated-orcid":false,"given":"Tina","family":"Felfeli","sequence":"additional","affiliation":[{"name":"Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; and"},{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260518","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1350-9462(01)00023-4","article-title":"Proliferative vitreoretinopathy: risk factors and pathobiology","volume":"21","author":"Pastor","year":"2002","journal-title":"Prog Retin Eye Res"},{"key":"R2-20260518","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0161-6420(83)34588-7","article-title":"The classification of retinal detachment with proliferative vitreoretinopathy","volume":"90","author":"Hilton","year":"1983","journal-title":"Ophthalmology"},{"key":"R3-20260518","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"R4-20260518","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R5-20260518","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J Comput Graphical Stat"},{"key":"R6-20260518","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ophtha.2008.05.016","article-title":"Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial","volume":"115","author":"Ahmadieh","year":"2008","journal-title":"Ophthalmology"},{"key":"R7-20260518","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1111\/aos.12429","article-title":"Oral colchicine for prevention of proliferative vitreoretinopathy: a randomized clinical trial","volume":"93","author":"Ahmadieh","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"R8-20260518","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0161-6420(01)00589-9","article-title":"Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial","volume":"108","author":"Asaria","year":"2001","journal-title":"Ophthalmology"},{"key":"R9-20260518","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.01.021","article-title":"Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial","volume":"124","author":"Banerjee","year":"2017","journal-title":"Ophthalmology"},{"key":"R10-20260518","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ajo.2008.05.002","article-title":"Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy","volume":"146","author":"Chang","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R11-20260518","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.ophtha.2004.05.036","article-title":"A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy","volume":"111","author":"Charteris","year":"2004","journal-title":"Ophthalmology"},{"key":"R12-20260518","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/112067211002000224","article-title":"Effect of oral prednisolone on visual outcomes and complications after scleral buckling","volume":"20","author":"Dehghan","year":"2010","journal-title":"Eur J Ophthalmol"},{"key":"R13-20260518","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/09273948.2019.1597894","article-title":"Intra-silicone oil injection of methotrexate in retinal reattachment surgery for proliferative vitreoretinopathy","volume":"28","author":"Falavarjani","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"R14-20260518","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.sjopt.2014.03.005","article-title":"Effect of intraoperative 5-fluorouracil and low molecular weight heparin on the outcome of high-risk proliferative vitreoretinopathy","volume":"28","author":"Ganekal","year":"2014","journal-title":"Saudi J Ophthalmol"},{"key":"R15-20260518","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00417-011-1919-y","article-title":"Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial","volume":"250","author":"Koerner","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R16-20260518","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1442-9071.2002.00554.x","article-title":"Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery","volume":"30","author":"Kumar","year":"2002","journal-title":"Clin Exp Ophthalmol"},{"key":"R17-20260518","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ophtha.2022.05.024","article-title":"Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial","volume":"129","author":"Schaub","year":"2022","journal-title":"Ophthalmology"},{"key":"R18-20260518","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archopht.125.9.1161","article-title":"Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy","volume":"125","author":"Schiff","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R19-20260518","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/s41433-019-0420-4","article-title":"The effect of single periocular injection of methylprednisolone and drainage of suprachoroidal fluid in the treatment of rhegmatogenous retinal detachment combined with choroidal detachment","volume":"33","author":"Wei","year":"2019","journal-title":"Eye (Lond)"},{"key":"R20-20260518","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ophtha.2006.08.042","article-title":"Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy","volume":"114","author":"Wickham","year":"2007","journal-title":"Ophthalmology"},{"key":"R21-20260518","first-page":"387","article-title":"Intravitreal methotrexate as an adjuvant in vitrectomy in cases of retinal detachment with proliferative vitreoretinopathy","volume":"263","author":"Rajan","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R22-20260518","doi-asserted-by":"crossref","first-page":"28842","DOI":"10.1038\/s41598-024-79708-1","article-title":"Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial","volume":"14","author":"Nourinia","year":"2024","journal-title":"Sci Rep"},{"key":"R23-20260518","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.oret.2024.05.016","article-title":"Intravitreal infliximab for the treatment of proliferative vitreoretinopathy (FIXER): a randomized controlled phase II trial","volume":"8","author":"Younes","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R24-20260518","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1089\/jop.2005.21.44","article-title":"Effects of retinoic acid on retinal pigment epithelium from excised membranes from proliferative vitreoretinopathy","volume":"21","author":"Wu","year":"2005","journal-title":"J Ocul Pharmacol Ther"},{"key":"R25-20260518","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0161-6420(95)31007-X","article-title":"The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy","volume":"102","author":"Fekrat","year":"1995","journal-title":"Ophthalmology"},{"key":"R26-20260518","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1159\/000529451","article-title":"Steroid drugs as an adjunct for reducing the incidence of proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery: a meta-analysis of randomized controlled studies","volume":"66","author":"Xu","year":"2023","journal-title":"Ophthalmic Res"},{"key":"R27-20260518","doi-asserted-by":"crossref","first-page":"e0214674","DOI":"10.1371\/journal.pone.0214674","article-title":"Biomarkers for PVR in rhegmatogenous retinal detachment","volume":"14","author":"Zandi","year":"2019","journal-title":"PLoS One"},{"key":"R28-20260518","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000371901","article-title":"The effects of ozurdex\u00ae (dexamethasone intravitreal implant) on experimental proliferative vitreoretinopathy","volume":"233","author":"Kuo","year":"2015","journal-title":"Ophthalmologica"},{"key":"R29-20260518","doi-asserted-by":"crossref","first-page":"e000293","DOI":"10.1136\/bmjophth-2019-000293","article-title":"Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy","volume":"4","author":"Benner","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"R30-20260518","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:00:35Z","timestamp":1779127235000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004789"}},"subtitle":["A Network Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004789","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}